

Literatur zum Artikel

Isolierte hypertherme Extremitätenperfusion mit rh TNF- α und Melphalan

1. Creech O Jr., Krentz ET, Ryan RF, Winblad JN (1958) Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. *Ann Surg* 148: 616–632
2. Schwarzbach MHM, Lehnert T, Willeke F, et al (1996) Ergebnisse der isolierten hyperthermen Extremitätenperfusion bei Weichteilsarkomen im Rahmen eines multimodalen Behandlungskonzeptes. *Chirurg* 67: 1237–1243
3. Verhoef C, Wilt, JHW, Grünhagen, DJ, et al (2007) Isolated limb perfusion with melphalan and TNF- α in the treatment of extremity sarcoma. *Curr Treat Options Oncol* 8: 417–427
4. Lienard D, Ewalenko P, Delmotte JJ, et al (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. *J Clin Oncol* 10: 52–60
5. Eggermont AM, Schraffordt Koops H, Klausner JM, et al (1996) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with local advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. *Ann Surg* 224: 756–764
6. Bonvalot S, Gronchi A (2011) ILP and RT: the study that will never be. *Ann Surg Oncol* 18: 303–305
7. Podleska LE, Taeger G, Steinau H-U (2013) Die isolierte Extremitätenperfusion. Lokales Therapieverfahren bei „inoperablen“ Weichgewebesarkomen und ausgedehnten malignen Melanomen. *CHAZ* 14: 255–258
8. Podleska LE, Schwindenhammer B, Grabellus F, et al (2017) Isolierte Extremitätenperfusions bei Liposarkomen: Histopathologisches Ansprechen und Subgruppenanalyse nach TNF-Melphalan-ILP. *Chirurg* [Epub ahead of print]
9. Eggermont AM (2003) Isolated limb perfusion in the management of locally advanced extremity soft tissue sarcoma. *Surg Oncol Clin N Am* 83: 371–384
10. Jakob J, Hohenberger P (2016) Role of isolated limb perfusion with recombinant Human Tumor Necrosis Factor alpha and Melphalan in locally advanced extremity soft tissue sarcoma. *Cancer* 122: 2624–2632
11. Schwarzbach MHM, Hormann Y, Hinz U, et al (2005) Results of limb-sparing surgery with vascular replacement for soft tissue sarcoma in the lower extremity. *J Vasc Surg* 42: 88–96
12. Grabellus F, Podleska LE, Sheu SY, et al (2013) Neoadjuvant treatment improves capsular integrity and the width of the fibrous capsule of high-grade soft-tissue sarcomas. *Eur J Surg Oncol* 39: 61–67
13. Herbert SH, Corn BW, Solin LJ, et al (1993) Limb-preserving treatment for soft tissue sarcomas of the extremities. The significance of surgical margins. *Cancer* 72: 1230–1238
14. Stojadinovic A, Leung D, Hoos A, et al (2002) Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. *Ann Surg* 235: 424–434
15. Suit HD, Mankin HJ, Wood WC, Proppe KH (1985) Preoperative, intraoperative, and postoperative radiation in the treatment of primary soft tissue sarcoma. *Cancer* 55: 2659–2667
16. Hoven-Gondrie ML, Thijssens KM, Geertzen JH, et al (2008) Isolated limb perfusions and external beam radiotherapy for soft tissue sarcoma of the extremity: long-term effects on normal tissue according to the LENT-SOMA scoring system. *Ann Surg Oncol* 15: 1502–1510
17. Lenk H, Tanneberger S, Muller U, et al (1989) Phase II clinical trial of high-dose recombinant human tumor necrosis factor. *Cancer Chemother Pharmacol* 24: 391–392
18. Folli S, Pelegrin A, Chalandon Y, et al (1993) Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. *Int J Cancer* 53: 829–836
19. De Wilt JH, ten Hagen TL, de Boeck G, et al (2000) Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. *Br J Cancer* 82: 1000–1003
20. Ruegg C, Yilmaz A, Bieler G, et al (1998) Evidence for the involvement of endothelial cell integrin alpha V beta 3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. *Nat Med* 4: 404–414
21. Wieberdink J, Benckhuysen C, Braat RP, et al (1982) Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. *Eur J Cancer Clin Oncol* 18: 905–910
22. Bonvalot S, Laplanche A, Lejeune F, et al (2005) Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? *Ann Oncol* 16: 1061–1068
23. Pennacchioli E, Deraco M, Mariani L, et al (2007) Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. *Ann Surg Oncol* 14: 553–559
24. Rastrelli M, Campana LG, Valpione S, et al (2016) Hyperthermic isolated limb perfusion in local advanced limb soft tissue sarcoma: a 24-year single-centre experience. *Int J Hyperthermia* 32: 165–172
25. Cherix S, Speiser M, Matter M, et al (2008) Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients. *J Surg Oncol* 98: 148–155
26. Jakob J, Tunn PU, Hayes AJ, et al (2014) Oncological outcome of primary non-metastatic soft tissue sarcoma treated by neoadjuvant isolated limb perfusion and tumor resection. *J Surg Oncol* 109: 786–790
27. Schwindenhammer B, Podleska LE, Kutritz A, et al (2013) The pathologic response of resected synovial sarcomas to hyperthermic isolated limb perfusion with melphalan and TNF-alpha: a comparison with the whole group of resected soft tissue sarcomas. *World J Surg Oncol* 11: 185
28. Grabellus F, Kraft C, Sheu-Grabellus SY, et al (2011) Tumor vascularization and histopathologic regression of soft tissue sarcomas treated with isolated limb perfusion with TNF-alpha and melphalan. *J Surg Oncol* 103: 371–379
29. Schwarzbach MHM, Hinz U, Dimitrakopoulou-Strauss A, et al (2005) Prognostic significance of preoperative [¹⁸F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. *Ann Surg* 241: 286–294
30. Schwarzbach MHM, Dimitrakopoulou-Strauss A, Willeke F, et al (2000) Clinical value of [¹⁸F] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. *Ann Surg* 231: 380–386
31. Schwarzbach MHM, Dimitrakopoulou-Strauss A, Mechtersheimer G, et al (2001) Prospective assessment of masses suspicious for liposarcomas by fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET). *Anticancer Res* 21: 3609–3614
32. Enzinger FM, Weiss SW (1995) *Soft tissue tumors*, 3rd ed. Mosby, St Louis
33. Schwarzbach MH, Koesters R, Germann A, et al (2004) Comparable transcription capacities and differential gene expression patterns of variant FUS/CHOP fusion transcripts derived from soft tissue liposarcomas. *Oncogene* 23: 6798–6805
34. Hoven-Gondrie ML, Bastiaabbe E, van Ginkel RJ, et al (2011) TNF dose reduction and shortening of duration of isolated limb perfusion for locally advanced soft tissue sarcoma of the extremities is safe and effective in terms of long-term patient outcome. *J Surg Oncol* 103: 648–655
35. Deroose JP, Eggermont AM, van Geel AN, et al (2011) Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. *J Clin Oncol* 29: 4036–4044